Furthermore, some other trials are assessing the combination of TIM-3 with anti-PD-1 mAbs, such as anti-TIM-3/PD-L1 and anti-TIM-3/PD-1 bispecific antibodies (i.e., LY3415244 and RO7121661), for therapy to apply to solid and hematological malignancies [60,92,93]. Here, HAVCR2 is linked to hematologic disorder.